| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_84d9adaa7e7ce01ce8020f5c721aba10 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7016
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-702
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-702
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7016
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-70 |
| filingDate |
1996-04-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2002-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_962c21894015f4ed6ab8f6a36819553a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3e15051cb3cd6d38701c0fb1285f0f66
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9b69afad75973567af0a8d2bc4e282f0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a5bf705ac4174a42a21682b2c49e3410
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_15679fa8da134b4e7468130ea0292d9d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_796cbc0b1eabb1f9189dfb5cec4a8387 |
| publicationDate |
2002-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2217157-C |
| titleOfInvention |
Inhibition of c. difficile infections by indigestible oligosaccharides |
| abstract |
The primary etiology of antibiotic-associated diarrhea (also known as pseudomembranous colitis) has been recognized as Clostridium difficile. It is believed that the indigenous microflora of a healthy individual suppresses the normally present C. difficile. However, when the indigenous microflora are disrupted (e.g., during antibiotic treatment) overgrowth of C. difficile may occur causing diarrhea and colitis. Treatment of C. difficile with antibiotics has proven effective, but many times relapse occurs; and dehydration due to diarrhea is an exacerbating problem. It has been suggested that normalization of the microflora will inhibit C. difficile relapse. Indigestible oligosaccharides have been shown to inhibit C. difficile infection. An oral rehydration solution containing such indigestible oligosaccharides also provides fluid and electrolyte replacement. |
| priorityDate |
1995-04-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |